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Abstract
 
Hepatocellular carcinomas (HCCs) mainly develop from liver cirrhosis and severe liver fibrosis
that are established with long-lasting inflammation of the liver. Silencing of the suppressor of
the cytokine signaling-1 (SOCS1) gene, a negative regulator of cytokine signaling, by DNA
methylation has been implicated in development or progress of HCC. However, how SOCS1
contributes to HCC is unknown. We examined SOCS1 gene methylation in 
 
 
 
200 patients
with chronic liver disease and found that the severity of liver fibrosis is strongly correlated with
SOCS1 gene methylation. In murine liver fibrosis models using dimethylnitrosamine, mice
with haploinsufficiency of the SOCS1 gene (SOCS1
 
   
 
 mice) developed more severe liver
fibrosis than did wild-type littermates (SOCS1
 
   
 
 mice). Moreover, carcinogen-induced HCC
development was also enhanced by heterozygous deletion of the SOCS1 gene. These findings
suggest that SOCS1 contributes to protection against hepatic injury and fibrosis, and may also
protect against hepatocarcinogenesis.
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Introduction
 
Hepatocellular carcinoma (HCC) is one of the most common
cancers with poor prognosis. Chronic infection with hepa-
titis C virus (HCV) is a major risk factor for development
of HCC. In general, HCC develops only after one or more
decades of HCV infection, and the increased risk is restricted
largely to patients with cirrhosis or advanced fibrosis. Al-
though HCV-infected persons with mild or nonhepatic
fibrosis are not likely to get HCC, once cirrhosis is estab-
lished, HCC develops at an annual rate of 1–4% per year
(1), and there is a strong correlation between liver fibrosis
and HCC development (2).
Suppressor of cytokine signaling-1 (SOCS1), also known
as JAK binding protein, is an intracellular protein that in-
hibits JAK-analyzed mediated cytokine signaling by binding
to JAKs. (3–5). SOCS1-deficient mice (SOCS1
 
   
 
) die
within 3 wk after birth with fulminant hepatitis accompa-
nied with serious fatty degeneration (6, 7). The SOCS1
gene has been implicated as an antioncogene in hepatocar-
cinoma. Yoshikawa et al. reported aberrant methylation in
the CpG island of SOCS1 that correlated with its transcrip-
tion silencing in HCC cell lines (8). The incidence of aber-
rant methylation was 65% in the 26 human primary HCC
tumor samples analyzed. However, the molecular basis for
the development of HCC by SOCS1 gene silencing has
not been clarified.
Because HCC development follows severe liver fibrosis,
we examined SOCS1 methylation status in chronic liver
injury to determine if SOCS1 genetic alteration is involved
in liver fibrosis progression as well as in HCC. We found
that SOCS1 gene methylation occurred at the hepatitis
stage before the onset of HCC and highly correlated with
liver fibrosis. Furthermore, using mouse models, we dem-
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onstrated that SOCS1 gene deletion augments fibrosis asso-
ciated with liver damage, probably due to signal transducer
and activator of transcription (STAT1) 1 hyperactivation.
We propose that the SOCS1 gene is necessary for prevent-
ing hepatocarcinogenesis developed from chronic liver in-
jury and liver cirrhosis.
 
Materials and Methods
 
Patients and Histology.
 
A needle biopsy technique was used to
obtain liver biopsy specimens from HCC patients in the Depart-
ment of Internal Medicine of Kurume University Hospital and
the Nagata Hospital. Tissue biopsies were stored in 
 
 
 
70
 
 
 
C until
analysis. Informed consent was obtained from all the patients be-
fore biopsies were conducted. Histological evaluations of the
liver were based on 5–30-mm-long liver specimens obtained by
percutaneous biopsy using 0.8–1.4-gauge needles. The speci-
mens were fixed in a 10% formalin buffer and stained with he-
matoxylin-eosin. Biopsy specimens with signs of rejection were
excluded, and histological results were classified into four catego-
ries as follows: normal, lobular hepatitis, chronic hepatitis (de-
fined by piecemeal necrosis or fibrosis), and cirrhosis. The
METAVIR score was used to classify biopsy specimens, using
simplified scores for fibrosis (from F0, no fibrosis, to F4, cirrho-
sis; reference 9).
 
Methylation-specific PCR.
 
Genomic DNA was obtained from
liver biopsy samples using a standard method and bisulfite modifi-
cation of genomic DNA was performed as described previously
(10, 11). The bisulfite-treated DNA was amplified with either
a methylation-specific or unmethylation-specific primer as de-
scribed previously (8). To investigate the methylation state of
SOCS1 CpG DNA, we also performed methylation assays at
CpG-rich regions around the NotI landmark sites after the geno-
mic region in question had been digested with HpaII, which is
sensitive to cytosine methylation in the CCGG recognition se-
quence as described previously (12).
 
Mice and Other Animal Models.
 
The SOCS1-deficient mouse
has been described previously (13). For liver fibrosis model, di-
methylnitrosamine (DMN) was administrated into 6–8-wk-old
mice. Each mouse was given subsequently an intraperitoneal in-
jection of 10 
 
 
 
g DMN per gram of body weight three times a
week for 3 wk. The amount of DMN administered was adjusted
for body weight each week. 2 d after the third series of injections,
Figure 1. SOCS1 methylation in the liver of HCV pos-
itive patients and relationship to liver fibrosis and HCC.
(A) Examples of methylation-specific PCR of SOCS1.
Primer sets used for amplification are designated as un-
methylated (UM) or methylated (M). PCR was performed
using bisulfite-treated DNA from the paraffin-embedded
liver tissue and PLC/PFR/5 cells (hepatoma cell line) as
methylated positive control. (B) Quantification of SOCS1
mRNA levels by real-time RT-PCR in liver samples of
non-HCC ( ) and HCC ( ) regions with SOCS1 gene
methylation (n   15) and unmethylation (n   17). Meth-
ylation status was examined in non-HCC regions. Each
group was normalized to the G3PDH values. (C) Summary
of methylation status in patients and the HCC develop-
ment among these patients within 12 yr. (D) The number
of patients of each fibrosis score in methylation positive or
negative patient groups and the percentage of methylation
positive patients at each stage were plotted. (E) Serum
platelet counts in patients from methylation positive or
negative patient groups were scored. The bar indicates the
standard deviation. 
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venous blood was collected and the mice were killed. Hyaluronic
acid and alanine aminotransferase (ALT) were measured using
standard methods. The liver was fixed with either 10% formalde-
hyde for histological examination or frozen immediately in liquid
nitrogen for immunoblotting and the extraction of collagen as
described previously (14). Liver fibrosis was quantified with Sirius
red by digital image analysis as described previously (15). For car-
cinogenic treatment, 4-wk-old mice were given an intraperito-
neal injection of 100 
 
 
 
g diethylnitrosamine (DEN) per gram of
body weight once a week for 6 wk (16). 9 mo after the first in-
jection of DEN, these mice were killed, and a 3-mm-thick sec-
tion from each liver was prepared. An identical tumor from dif-
ferent sections was excluded for counts. The morphology of
hepatocellular neoplasms was classified according to cell size,
tinctorial properties of the cytoplasm, pattern of growth, and
other morphological features as described previously (17). All ex-
periments using these mice were approved by and performed ac-
cording to the guidelines of the animal ethics committee of Ky-
ushu University. Immunoblot analysis was performed using 20
 
 
 
g of total liver protein as described previously (18).
 
Statistical Analysis.
 
For statistical analysis, we used the Stu-
dent’s 
 
t
 
 test, and a 95% confidence limit (defined as P 
 
 
 
 0.05)
was taken to be significant.
 
Online Supplemental Material.
 
The results of experiments,
which complement the data presented in the paper, are shown in
Figs. S1 and S2. Fig. S1 shows sequencing of 58 CpG sites in the
467-bp genomic DNA from patients with bisulfite treatment.
Fig. S2 shows a gross image of the liver and sections with he-
matoxylin-eosin staining of hepatocarcinomas in DEN-treated
SOCS1
 
   
 
 mice. Online supplemental material is available at
http://www.jem.org/cgi/content/full/jem.20031675/DC1.
 
Results and Discussion
 
SOCS1 Methylation Correlates with Liver Fibrosis.
 
SOCS1
gene deletion in mice results in severe liver inflammation,
probably because of hyper IFN
 
 
 
/STAT1 signaling (7). Se-
vere liver fibrosis due to chronic liver inflammation is
shown to be a major cause of HCC development after
HCV infection (19). Therefore, we examined the methyla-
tion state in the CpG island of the SOCS1 gene in 
 
 
 
200
human liver biopsy samples with HCV-associated chronic
hepatitis and liver cirrhosis before the onset of HCC.
Among these, 209 samples of DNA could be evaluated
for methylation status. Representative methylation-specific
PCR results are shown in Fig. 1 A. Sequencing analysis of
58 CpG sites in the 467-bp genomic DNA with bisulfite
treatment revealed that frequent methylation occurred in
the latter half (nucleotides 200–400) of the region, whereas
no methylation was detected in the PCR product deter-
Figure 2. Liver fibrosis is enhanced in SOCS1    mice. (A) Survival rate in DMN-treated mice. DMN (10  g/g body weight) was intraperitoneally
injected on the indicated day (arrows), and mortality was examined. The numbers of mice examined and survived on day 21 are shown. (B) Serum ALT
values were significantly greater in SOCS1    than in SOCS1 /  mice after 3 wk of DMN treatment. (C) Histological and immunohistological analysis of
liver from mice treated with DMN. Sections of livers were examined using Azan and Sirius red staining and immunohistostaining with antibodies against
 -smooth muscle actin (SMA), TGF- 1, and fibronectin. (D) The surface area stained with Sirius red was quantified using digital image analysis. (E) Serum
hyaluronate levels in DMN-treated mice. Blood was collected 3 wk after DMN treatment. (B, D, and E) SOCS1    (n   6) and SOCS1    (n   8). 
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mined as methylation negative by methylation-specific
PCR (Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20031675/DC1). We confirmed the re-
duced expression of the SOCS1 gene in methylation posi-
tive livers using real-time PCR (Fig. 1 B). We also con-
firmed that SOCS1 expression in the HCC region was
lower than that in non-HCC region (Fig. 1 B).
As shown in Fig. 1 C, aberrant methylation of the
SOCS1 gene was present in 45% (94/209) of hepatitis pa-
tients detected by methylation-specific PCR (8). These re-
sults were confirmed by digesting genome DNA with
methylation-sensitive enzymes (unpublished data and refer-
ence 12). These data indicate that DNA methylation in the
liver occurred before HCC onset in a substantial percent-
age of hepatitis patients.
Next, we compared the grade of fibrosis and SOCS1
methylation. The progression of liver fibrosis was classified
into four stages, from F1 to F4. As shown in Fig. 1 D, the
frequency of SOCS1 methylation was 32% in the F1 stage,
and it increased to nearly 60% in the F4 stage. The propor-
tion of methylation significantly increased with the ad-
vancement of liver fibrosis, suggesting that the frequency of
SOCS1 methylation correlated with the severity of liver fi-
brosis (Fig. 1 D). It has been reported that the platelet
count accurately predicts significant HCV-related fibrosis
(20). As shown in Fig. 1 E, the decrease in the platelet
number was greater in SOCS1 methylation-positive pa-
tients (P 
 
  
 
0.01). These data reveal that SOCS1 methyla-
tion in the liver correlates with the liver fibrosis induced by
hepatitis. Thus, we propose that at the earlier stages of
chronic liver injury, SOCS1 methylation occurs, and the
SOCS1 gene methylation ratio increases as the stage of fi-
brosis progresses.
 
SOCS1 Haploinsufficiency Enhanced Liver Fibrosis in
Mice.
 
To verify the relationship between reduced expres-
sion of SOCS1 and liver fibrosis, we used a DMN-induced
liver fibrosis model and mice carrying a heterozygous dele-
tion of the SOCS1 gene (SOCS1
 
   
 
) as a model of SOCS1
gene silencing. An intraperitoneal injection of DMN has
been shown to induce fatty degeneration of hepatocytes,
activation and proliferation of hepatic stellate cells (also
called Ito cells and lipocytes), infiltration by macrophages
(possibly Kupffer cells), and secretion of TGF-
 
 
 
, which
promotes fibrosis. First, we examined the mortality rate
after injection of DMN (Fig. 2 A). Approximately 50%
of mice with haploinsufficiency of the SOCS1 gene
(SOCS1
 
   
 
 mice) died within 3 wk, whereas 
 
 
 
90% of
SOCS1
 
   
 
 mice survived. Serum ALT levels in SOCS1
 
   
 
mice were higher than those in SOCS1
 
   
 
 mice, suggest-
ing that more severe liver damage occurred in SOCS1
 
   
 
mice. As shown in Fig. 2 C, DMN treatment resulted in
tissue remodeling with a matrix deposition mainly in the
centrilobular area and portal tract, as assessed histologically
(Azan staining and Sirius red staining) or by immunohis-
tostaining using specific antibodies against 
 
 
 
-smooth mus-
cle actin (SMA), TGF-
 
 
 
1, and fibronectin (Fig. 2 C).
These histological analyses indicate that SOCS1 heterozy-
gous deletion cooperatively enhanced fibrosis. We also esti-
mated fibrosis by quantitative measurement of Sirius red
staining (Fig. 2 D) and by measurement of serum hyal-
uronate levels (Fig. 2 E), a serum marker of the progression
of liver fibrosis in humans (21). These data indicate that
SOCS1 gene haploinsufficiency augmented DMN-induced
liver fibrosis. These findings also support the current notion
that hepatic stellate cells are transformed into myofibro-
blasts (expressing SMA) and secrete TGF-
 
 
 
, thereby stimu-
lating the production of an extracellular matrix and proba-
bly the proliferation of these cells.
Next, we used another chronic liver injury model in-
duced by a choline-deficient, L-amino acid–defined diet.
As shown in Fig. 3 (A and B), liver fibrosis, as assessed by
Azan and Sirius red staining, occurred more markedly in
SOCS1
 
   
 
 mice than in the control mice (SOCS1
 
   
 
). In
addition, the amount of total collagen, a marker of fibrosis,
in SOCS1
 
   
 
 mice was higher than that in the control
mice (Fig. 3 C, SOCS1
 
   
 
). Again, SOCS1 gene haploin-
sufficiency enhanced diet-induced liver fibrosis. These data
Figure 3. Fibrosis of the liver induced by a choline-deficient, L-amino
acid–defined diet. (A) Histology of livers from indicated genotypes of
mice fed a choline-deficient, L-amino acid-defined diet for 12 wk. Liver
sections were examined histologically using Azan and Sirius red staining.
(B) The surface area stained with Sirius red was quantitated using digital
image analysis (n   4). (C) Total collagen content of the liver of mice fed
a choline-deficient diet for 4 or 12 wk. The total collagen content is
shown with SD (n   4). 
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indicate that loss of the SOCS1 gene in the liver enhances
the liver fibrosis induced by liver damages.
 
Correlation between STAT Activation and DMN-induced
Liver Fibrosis.
 
After injection of DMN, plasma levels of a
wide variety of cytokines, including IL-6 and IFN
 
 
 
, were
dramatically elevated (22). To elucidate the molecular basis
of induction of liver fibrosis by SOCS1 gene silencing, we
examined the activation status of intercellular cytokine-sig-
naling molecules using Western blotting. As shown in Fig.
4 (A and B), RT-PCR confirmed the reduction of SOCS1
mRNA levels and elevated TGF-
 
 
 
 production in DMN-
treated SOCS1
 
   
 
 mice. Western blotting analysis indi-
cated that DMN injection induced phosphorylation of
STAT1, STAT3, STAT5, and ERK (Fig. 4 C). The most
striking correlation to fibrosis was elevated STAT1 activa-
tion and reduced STAT3 activation in SOCS1
 
   
 
 mice,
whereas STAT5 phosphorylation was almost equal be-
tween SOCS1
 
   
 
 and SOCS1
 
   
 
 mice. STAT1 may pro-
mote liver injury by inducing IRF1, whereas STAT3 pro-
tects cells from apoptosis by inducing Bcl-XL. Consistent
with strong STAT1 activation and decreased STAT3 acti-
vation in SOCS1
 
   
 
 mice, induction of the Bcl-XL protein
was diminished, whereas the induction of the IRF-1 pro-
tein was significantly enhanced in these mice. Interestingly,
SOCS3 expression was enhanced in SOCS1
 
   
 
 mice. Be-
cause SOCS3 is a negative regulator of gp130-mediated
signals (23), elevated expression of SOCS3 may explain the
reduced STAT3 activation in these mice.
In the ConA-induced hepatitis model, as in the DMN-
induced fibrosis model, both STAT1 and STAT3 are acti-
vated (24). Using STAT1-, IFN
 
 
 
-, and IL-6–deficient
mice, Hong et al. proposed that STAT1 promotes liver in-
jury by inducing the expression of proapoptotic IRF-1
protein, whereas STAT3 activation prevents liver damage
by inducing antiapoptotic signals, such as Bcl-XL (24). Our
data on STAT1 and STAT3 activation induced by DMN
treatment are consistent with that proposal. Increased acti-
vation of STAT1 induces IRF-1 and reduced activation of
STAT3 leads decrease in Bcl-XL expression, and these, at
least in part, may account for a severe liver injury in
SOCS1
 
   
 
 mice. Therefore, SOCS1 deletion may cooper-
atively promote liver damage and fibrosis by activation of
STAT1 and repression of STAT3.
 
Hepatocarcinogenesis in SOCS1
 
   
 
 Mice.
 
Next, we ex-
amined if the SOCS1 loss of heterozygosity promotes
hepatocarcinogenesis. We induced liver tumors by a well-
established chemical carcinogenesis protocol using DEN.
Because nitrate and nitrosamine synthesis are increased in
viral hepatitis (25), DEN-induced HCC is thought to be an
adequate model of hepatocarcinogenesis due to viral hepa-
titis. After 9 mo, liver tumors were developed. The num-
ber of tumors, including HCC in the SOCS
 
   
 
 mice, was
higher than the number of tumors in the control mice (Fig.
5). As has been found in human HCC, male mice devel-
oped more tumors than did female. Large tumor nodules
were macroscopically visible in SOCS1
 
   
 
 mice (Fig.
S2, available at http://www.jem.org/cgi/content/full/
jem.20031675/DC1). These tumors, whitish in color and
discriminated from surrounding tissues, were consisted of
hyperplastic nodules with no or mild dysplasia and typical
HCCs that had a trabecular structure with or without fatty
degeneration (Fig. S2). These data indicate that SOCS1
gene haploinsufficiency correlates with increased cancer
risk in the liver.
Our work demonstrated that SOCS1 gene haploinsuffi-
ciency in mice and SOCS1 gene silencing by DNA meth-
Figure 4. Activation of STATs and proapoptotic and antiapoptotic
proteins in DMN-induced liver fibrosis. (A) Expression levels of SOCS1
mRNA were quantitated using real-time RT-PCR. The expression was
normalized as a ratio using G3PDH mRNA as a housekeeping gene (n = 6).
Each group of mice was sacrificed 3 wk after treatment with DMN. (B) RT-
PCR analysis for TGF-  and IL-6 levels. Total RNA were prepared and
analyzed using indicated primer sets. (C) Activation of STATs, SOCS1,
and proapoptotic or antiapoptotic proteins in the liver. Total liver protein
extracts were prepared and analyzed by Western blotting using indicated
antibodies. Data are representative of three independent experiments with
similar results. p, phosphorylated form.
Figure 5. Hepatocarcinogenesis
in SOCS1    mice. Liver tumors of
SOCS1    mice 9 mo after DEN-
induced tumor initiation. The total
number of tumors (unshaded bars)
including HCC (shaded bars) were
scored from 100 series of 3-mm sec-
tions from livers of four female (f)
and male (m) mice, with the indi-
cated genotypes. 
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ylation in humans highly correlate with increased liver
damage, liver fibrosis, and hepatocarcinogenesis, although
it is unclear how liver injury contributes to fibrosis and
hepatocarcinogenesis at present. Although the mechanism
of aberrant gene methylation is unknown, it may be caused
by increases in de novo methylation activity or by a defect
of the protection mechanism against de novo methylation.
However, there is no evidence of imprinting of the SOCS1
gene. Therefore, from data of SOCS1 gene methylation
status of chronic hepatitis and liver cirrhosis sample, we
propose that the SOCS1 gene is likely to be epigenetically
methylated as liver fibrosis progresses, just as the methyla-
tion of the p16 (INK4A) tumor suppressor gene occurs
during liver fibrosis (26).
It has been shown that HCC development of a person
with HCV chronic infection is correlated with the severity
of liver fibrosis. However, we found that SOCS1 methyla-
tion (P 
 
  
 
0.0015) is highly correlated with hepatocarcino-
genesis, which is comparable to the correlation between fi-
brosis and HCC (P 
 
  
 
0.0011). These observations support
our proposal that SOCS1 methylation can be a useful diag-
nostic indicator for HCC risk. SOCS1 methylation status
may also partly explain the difference in individuals in the
clinical course after hepatitis virus infection.
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